Teva receives EC approvals for PONLIMSI, DEGEVMA

Teva (TEVA) Pharmaceuticals International, a subsidiary of Teva Pharmaceutical Industries, announced that the European Commission, EC, has granted marketing authorizations for its two denosumab biosimilar candidates – PONLIMSI, a biosimilar to Prolia and DEGEVMA, a biosimilar to Xgeva, following the positive opinion of the Committee for Medicinal Products for Human Use, CHMP, earlier this year. Teva plans to launch both products in key European markets in the coming months. The approval represents an important step in advancing Teva’s Pivot to Growth strategy, reinforcing the company’s dedication to broadening access to biosimilar medicines for patients.